Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jessica Gartrell

Showing results (21-30 of 24) with videos related to

Pageof 3
Sort By:
You have reached the last page of results.This site can display upto 24 results.
Cell Chemical Biology|December 9, 2022
Allosteric regulation of DNA binding and target residence time drive the cytotoxicity of phthalazinone-based PARP-1 inhibitorsMoriah R Arnold, Marie-France Langelier, Jessica Gartrell, et al.
Cancers|September 13, 2025
ESFT13: A Phase II Study Evaluating the Addition of Window and Maintenance Therapy to a Standard Chemotherapy Backbone for the Treatment of High-Risk Ewing SarcomaJessica Gartrell, Fariba Navid, Xiaomeng Yuan, et al.
European Journal of Cancer (Oxford, England : 1990)|August 16, 2020
A phase I trial of talazoparib and irinotecan with and without temozolomide in children and young adults with recurrent or refractory solid malignanciesSara M Federico, Alberto S Pappo, Natasha Sahr, et al.
Molecular Cancer Therapeutics|August 20, 2021
SLFN11 is Widely Expressed in Pediatric Sarcoma and Induces Variable Sensitization to Replicative Stress Caused By DNA-Damaging AgentsJessica Gartrell, Marcia Mellado-Largarde, Michael R Clay, et al.
Pageof 3

Showing results (21-30 of 24) with videos related to

Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 24 results.
Cell Chemical Biology|December 9, 2022
Allosteric regulation of DNA binding and target residence time drive the cytotoxicity of phthalazinone-based PARP-1 inhibitorsMoriah R Arnold, Marie-France Langelier, Jessica Gartrell, et al.
Cancers|September 13, 2025
ESFT13: A Phase II Study Evaluating the Addition of Window and Maintenance Therapy to a Standard Chemotherapy Backbone for the Treatment of High-Risk Ewing SarcomaJessica Gartrell, Fariba Navid, Xiaomeng Yuan, et al.
European Journal of Cancer (Oxford, England : 1990)|August 16, 2020
A phase I trial of talazoparib and irinotecan with and without temozolomide in children and young adults with recurrent or refractory solid malignanciesSara M Federico, Alberto S Pappo, Natasha Sahr, et al.
Molecular Cancer Therapeutics|August 20, 2021
SLFN11 is Widely Expressed in Pediatric Sarcoma and Induces Variable Sensitization to Replicative Stress Caused By DNA-Damaging AgentsJessica Gartrell, Marcia Mellado-Largarde, Michael R Clay, et al.
Pageof 3